Overview
Kynurenine is the primary metabolite of the kynurenine pathway, which handles ~95% of tryptophan catabolism in the body. While serotonin gets more attention, the kynurenine pathway is quantitatively dominant — and its downstream metabolites span the range from neuroprotective to neurotoxic. The pathway's rate-limiting enzymes (IDO1, IDO2, TDO) all require heme iron, creating a direct link between metal biology and neuroimmune signaling.
In the WikiBiome context, the kynurenine pathway is the mechanistic bridge between inflammation, metal dyshomeostasis, and neuropsychiatric disease: metal-driven inflammation upregulates IDO1, shunting tryptophan from serotonin to kynurenine, generating neurotoxic quinolinic acid that itself chelates iron and catalyzes fenton chemistry — a self-amplifying cycle.
The Kynurenine Pathway
``` Tryptophan │ ├──[IDO1/IDO2 (heme iron; IFN-gamma-inducible)]──→ Kynurenine │ │ └──[TDO (heme iron; liver, constitutive)]──────────────┘ │ ┌──────────────────────────────┤ │ │ Kynurenic acid (KA) 3-Hydroxykynurenine (3-HK) [neuroprotective] [neurotoxic] [NMDA antagonist] [generates free radicals] │ Quinolinic acid (QUIN) [potent neurotoxin] [NMDA agonist, excitotoxin] [chelates iron → Fenton] ```
Key Metabolites
| Metabolite | Function | Clinical Relevance |
|---|---|---|
| Kynurenine | ahr ligand; immune modulator | Elevated in inflammation; AhR activation supports Treg differentiation |
| Kynurenic acid (KA) | Neuroprotective; NMDA receptor antagonist | Depleted in ASD (q=0.02); protective against excitotoxicity |
| 3-Hydroxykynurenine (3-HK) | Neurotoxic; generates free radicals | Elevated in neuroinflammation |
| Quinolinic acid (QUIN) | Potent neurotoxin; NMDA agonist; excitotoxin | Elevated in MS relapses; chelates iron and catalyzes Fenton chemistry |
The KA/QUIN Ratio
The balance between kynurenic acid (neuroprotective) and quinolinic acid (neurotoxic) determines net neurological impact. Inflammation shifts the pathway toward QUIN by upregulating enzymes in the neurotoxic branch.
Iron Dependency and Metal Connections
IDO1 and TDO Require Heme Iron
Both rate-limiting enzymes contain heme iron in their active sites. This creates multiple metal-kynurenine interactions:
- Iron deficiency may impair IDO1/TDO activity, paradoxically reducing kynurenine production.
- Iron excess supports IDO1 activity during inflammation, amplifying tryptophan diversion.
- Metal-induced inflammation (via NF-kB, TLR4) upregulates IFN-gamma, which induces IDO1, systematically shifting the pathway toward neurotoxic outputs [1].
Quinolinic Acid Chelates Iron
QUIN binds iron and forms QUIN-Fe complexes that catalyze Fenton chemistry, generating hydroxyl radicals in neural tissue [1]. This is a direct metal-neuroinflammation link: the kynurenine pathway not only responds to metal-driven inflammation but actively amplifies iron toxicity through its end product.
Microbiome Modulation
IDO1 Regulated by SCFAs
butyrate and other SCFAs modulate IDO1 expression, linking SCFA-producing commensal health to kynurenine pathway regulation [2]. Dysbiosis-driven SCFA depletion removes this brake on IDO1.
3-IAld Competes with Kynurenine for AhR
3-Indolealdehyde (3-IAld), produced by lactobacillus species, competes with L-kynurenine for AhR binding and tips tryptophan metabolism toward serotonin production via TPH1 induction [3]. Loss of Lactobacillus (common in dysbiosis) removes this competition, allowing kynurenine to dominate AhR signaling.
Immune Tolerance
The kynurenine pathway supports Treg differentiation and immune tolerance via AhR activation. Impairment of this pathway (as observed in long covid and ME/CFS) favors Th17 dominance and autoimmunity [4].
Conditions Associated
| Condition | Kynurenine Pathway Alteration | Source |
|---|---|---|
| depression | Elevated kynurenine/tryptophan ratio (p=0.008) | [5] |
| autism spectrum disorder | Kynurenate significantly depleted (q=0.02) | [6] |
| multiple sclerosis | QUIN elevated during relapses; IDO modulated by SCFAs | [2] |
| parkinsons disease | Tryptophan diverted to kynurenine; QUIN-iron Fenton | [1] |
| long covid / ME/CFS | Reduced kynurenine products; impaired AhR signaling; Treg failure | [4] |
| schizophrenia | FMT from SCZ patients altered kyn catabolism in mice | [7] |
| cerebral palsy | Reduced tryptophan pool consistent with kyn/serotonin depletion | [8] |
| fibromyalgia | Altered kynurenine pathway in FM-IBS overlap | |
| postpartum depression | IDO1 induction during postpartum inflammation |
Cross-References
- tryptophan metabolism — Parent pathway
- serotonin — Competing pathway for tryptophan
- ahr — Kynurenine as AhR ligand; 3-IAld competition
- indoles — Third tryptophan metabolic pathway
- iron — IDO1/TDO heme iron dependency; QUIN-Fe Fenton
- fenton chemistry — QUIN-iron complexes catalyze Fenton reaction
- oxidative stress — Downstream of QUIN neurotoxicity
- inflammation — IFN-gamma drives IDO1 induction
- microbiome derived metabolites — SCFAs modulate IDO1; 3-IAld competes with kynurenine
- gut brain axis — Kynurenine pathway as neuroimmune signaling axis